Skip to main content
BNXTF
OTC Life Sciences

BioNxt Seeks Up to $2.5M in Unit Placement Priced 34% Above Last Trade

Tom Rudovsky · Reported by ACCESS Newswire
Sentiment info
Negative
Importance info
7
Price
$0.187
Mkt Cap
$25.422M
52W Low
$0.1
52W High
$0.8
52W Position info
87% above low
Off High info
77% below high
Rel. Volume info
4.2× avg
Market data snapshot near publication time

BNXTF sits 87% above its 52-week low of $0.1 on elevated volume (4.2× avg).

Summary

BioNxt is raising up to $2.5M through a non-brokered placement of 10,000,000 units at $0.25 each, with each unit carrying a share and a warrant exercisable at $0.50 for 24 months. The $0.25 unit price sits well above the $0.1868 last trade, so the deal is priced at a premium to the market rather than a discount — unusual for a microcap raise and a sign the company is anchoring on its warrant-heavy structure. The raise is large relative to the company's roughly $25M market cap and will be dilutive if fully subscribed, with up to 8% cash finder's fees and 8% finder's warrants adding further cost. Proceeds are earmarked for European R&D, including a planned human clinical study, plus working capital. Closing is in tranches and still needs CSE acceptance, so timing and final size are not locked in.

At the time of this announcement, BNXTF was trading at $0.19 on OTC in the Life Sciences sector, with a market capitalization of approximately $25.4M. The 52-week trading range was $0.10 to $0.80. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.


Price Chart

Share this article

Copied!

BNXTF - Latest Insights